Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-11-19 00:00:00 ET · period of report 2025-11-17 · accession 0000875320-25-000236 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-19 | 2025-11-17 | VRTX | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | S - Sale | $434.58 | -2,500 | 16.9K | -13% | -$1.09M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-17 | S | D | 2,500 | $434.58 | 16,852 | D | — | — |